October 17, 2026

Newsletter

The European Post

Policy • Diplomacy • strategic insight

LATEST
Imports Lift Euro Area Trade Deficit To €16.1 Billion In AugustPoverty And Social Exclusion Top 54 percent In Guyane As EU Gap WidensRegions Seek Binding Role In Cohesion Policy Partnership PlansMontenegro EU Accession Reaches 21 Closed Chapters, 12 To GoRail Operators Resist Deeper Cuts To The EU Transport BudgetAlbania EU Accession Gains Fourth Closed Chapter And A 2027 GoalPostponed EU-GCC Summit Leaves Gulf Partnership Without A DateHouse Price Index Shows Portugal Surging While France SlipsBeating Cancer Plan Report Pushes Tougher Tobacco RulesChina Hybrid Car Quota Gives Brussels A Fragile TruceChips Act 2.0 Shifts EU Semiconductor Policy Toward Chip DemandMinisters Seal EU Pharmaceutical Reform After Two Decades Of DebateCouncil Adopts EU Return Regulation With Hubs And Longer DetentionRiver Basin Management Plans Expose Water PollutionEEA Competitiveness Report Ties Europe’s Growth To NatureEurostat Travel Data Shows Europeans Still Holiday At Home2027 EU Budget Vote Looms As Parliament Adds €1.17 Billion To DraftEU Sanctions Circumvention Crackdown Lists Twelve Russia Supply LinksTunisia Migration Deal Draws Rights Scrutiny And Calls For A RewriteLibya Elections Commission Deal Tests EU Support For UN RoadmapImports Lift Euro Area Trade Deficit To €16.1 Billion In AugustPoverty And Social Exclusion Top 54 percent In Guyane As EU Gap WidensRegions Seek Binding Role In Cohesion Policy Partnership PlansMontenegro EU Accession Reaches 21 Closed Chapters, 12 To GoRail Operators Resist Deeper Cuts To The EU Transport BudgetAlbania EU Accession Gains Fourth Closed Chapter And A 2027 GoalPostponed EU-GCC Summit Leaves Gulf Partnership Without A DateHouse Price Index Shows Portugal Surging While France SlipsBeating Cancer Plan Report Pushes Tougher Tobacco RulesChina Hybrid Car Quota Gives Brussels A Fragile TruceChips Act 2.0 Shifts EU Semiconductor Policy Toward Chip DemandMinisters Seal EU Pharmaceutical Reform After Two Decades Of DebateCouncil Adopts EU Return Regulation With Hubs And Longer DetentionRiver Basin Management Plans Expose Water PollutionEEA Competitiveness Report Ties Europe’s Growth To NatureEurostat Travel Data Shows Europeans Still Holiday At Home2027 EU Budget Vote Looms As Parliament Adds €1.17 Billion To DraftEU Sanctions Circumvention Crackdown Lists Twelve Russia Supply LinksTunisia Migration Deal Draws Rights Scrutiny And Calls For A RewriteLibya Elections Commission Deal Tests EU Support For UN Roadmap
October 17, 2026

Newsletter

The European Post

Policy • Diplomacy • strategic insight

LATEST
Imports Lift Euro Area Trade Deficit To €16.1 Billion In AugustPoverty And Social Exclusion Top 54 percent In Guyane As EU Gap WidensRegions Seek Binding Role In Cohesion Policy Partnership PlansMontenegro EU Accession Reaches 21 Closed Chapters, 12 To GoRail Operators Resist Deeper Cuts To The EU Transport BudgetAlbania EU Accession Gains Fourth Closed Chapter And A 2027 GoalPostponed EU-GCC Summit Leaves Gulf Partnership Without A DateHouse Price Index Shows Portugal Surging While France SlipsBeating Cancer Plan Report Pushes Tougher Tobacco RulesChina Hybrid Car Quota Gives Brussels A Fragile TruceChips Act 2.0 Shifts EU Semiconductor Policy Toward Chip DemandMinisters Seal EU Pharmaceutical Reform After Two Decades Of DebateCouncil Adopts EU Return Regulation With Hubs And Longer DetentionRiver Basin Management Plans Expose Water PollutionEEA Competitiveness Report Ties Europe’s Growth To NatureEurostat Travel Data Shows Europeans Still Holiday At Home2027 EU Budget Vote Looms As Parliament Adds €1.17 Billion To DraftEU Sanctions Circumvention Crackdown Lists Twelve Russia Supply LinksTunisia Migration Deal Draws Rights Scrutiny And Calls For A RewriteLibya Elections Commission Deal Tests EU Support For UN RoadmapImports Lift Euro Area Trade Deficit To €16.1 Billion In AugustPoverty And Social Exclusion Top 54 percent In Guyane As EU Gap WidensRegions Seek Binding Role In Cohesion Policy Partnership PlansMontenegro EU Accession Reaches 21 Closed Chapters, 12 To GoRail Operators Resist Deeper Cuts To The EU Transport BudgetAlbania EU Accession Gains Fourth Closed Chapter And A 2027 GoalPostponed EU-GCC Summit Leaves Gulf Partnership Without A DateHouse Price Index Shows Portugal Surging While France SlipsBeating Cancer Plan Report Pushes Tougher Tobacco RulesChina Hybrid Car Quota Gives Brussels A Fragile TruceChips Act 2.0 Shifts EU Semiconductor Policy Toward Chip DemandMinisters Seal EU Pharmaceutical Reform After Two Decades Of DebateCouncil Adopts EU Return Regulation With Hubs And Longer DetentionRiver Basin Management Plans Expose Water PollutionEEA Competitiveness Report Ties Europe’s Growth To NatureEurostat Travel Data Shows Europeans Still Holiday At Home2027 EU Budget Vote Looms As Parliament Adds €1.17 Billion To DraftEU Sanctions Circumvention Crackdown Lists Twelve Russia Supply LinksTunisia Migration Deal Draws Rights Scrutiny And Calls For A RewriteLibya Elections Commission Deal Tests EU Support For UN Roadmap

Faster Trials Anchor The European Biotech Act As Act II Takes Shape

Jóhannes Guðnason
Legislative Affairs Editor, Health and Wellbeing

Leiden: The European Biotech Act is moving toward negotiations between Parliament and the Council while the Commission already works on a second act. The Commission published the first proposal on 16 December 2025, and commentators expect trilogue talks to start in the fourth quarter of 2026, with adoption not before the end of the year. On 12 October 2026, the Commission held a stakeholder workshop in Brussels on Biotech Act II.

The case for the European Biotech Act rests on weak numbers. The Union holds a 7% share of global health biotech venture capital, and its share of commercial clinical trials fell from 22% to 12% over the past decade. Multinational trial approvals take 113 days on average in the EU, against 60 days in other regions.

The proposal attacks that gap with faster timelines. Approval for multinational trials would fall from 106 to 76 days, and from 75 to 47 days when no request for more information arises. The extra 50-day assessment period for advanced therapy medicinal products would disappear. A voluntary pilot called FAST-EU has run within the current rules since January 2026, involves 23 member states and aims for a decision within 70 days.

Beyond trials, the European Biotech Act creates regulatory sandboxes for clinical trials, novel health biotech products, substances of human origin, food and feed safety and veterinary medicines. Biomanufacturing projects could win strategic project status, with permit-granting capped at 10 months, or high-impact status, capped at 8 months. A 12-month extension of the supplementary protection certificate would apply to medicines developed through biotechnology processes and to advanced therapies.

Money and data complete the European Biotech Act package. An EU Health Biotechnology Investment Pilot, run with the European Investment Bank Group, would offer equity and venture-style debt to help companies scale. A harmonised GDPR legal basis would cover personal data in clinical trials, and the European Data Protection Board and Supervisor broadly supported the idea in Joint Opinion 3/2026 of 10 March while asking for clearer roles and safeguards.

Biotech Act II looks beyond medicine. The 12 October workshop updated stakeholders on call-for-evidence results and discussed preliminary policy options for industrial biotechnology and biomanufacturing, including the move from fossil-based to bio-based feedstocks. The act builds on the 2024 communication on biotechnology, the 2025 chemicals industry action plan and the European Bioeconomy Strategy of November 2025. The Commission has not published an adoption date.

Researchers and companies now wait for lawmakers. Parliament and the Council must settle trial timelines, data rules and funding before sponsors see any change. The European Biotech Act will show whether faster approvals can help Europe keep its trials and start-ups at home.

Comments